A recent large study has shown that the new drug Entresto has a very positive effect on patients with heart failure: patients are able to live longer and are less often hospitalized due to heart failure. This is probably a medical progression in the treatment of chronic heart failure.
The study: Entresto vs. Enalapril
A global study was recently conducted (PARADIGM-HF study) among more than 8,000 patients suffering from heart failure. The objective of this study was to compare Entresto with the other drug Enalapril in patients with a reduced pump function, or ejection fraction.
Enalapril belongs to the ACE-inhibitors that reduce high blood pressure and improves the pump function of the heart.
For an ejection fraction, a percentage indicates how much blood is pumped from the left or the right ventricle. This percentage provides an indication on the strength of the heart muscle: healthy people usually have an ejection fraction of 60 to 70%, 40% is still reasonably normal, but when it measures 30%, it may possibly indicate heart failure.
ENTRESTO belongs to the new pharmaceutical class of ARNi (Angiotensin Receptor Neprilysin inhibitors). It is a molecule that disintegrates in 2 different substances in the human body: Sacubitril and Valsartan. How does it work? See below video.
RAAS = Renin Angiotensin Aldosterone System
NEP = enzyme Neprilysin
Drug and side effects
Note: the drug Entresto should not be used at the same time as ACE-inhibitors. You can only start taking Entresto 36 hours after taking ACE-inhibitors. The drug Entresto consists of 3 different dosages and is usually taken twice a day. The most common side effects (similar to Enalapril) of Sacubitril/Valsartan are low blood pressure, abnormally high potassium levels and deterioration of the kidneys function.
Always ask your doctor, pharmacy specialist or nurse about the correct advice
on using Entresto and please read first the package insert.
Do you have any question about this Blog article? Please do not hesitate to contact us.